TGF-β1 enhances susceptibility to GPX4 inhibition in well-differentiated HCC cells, suggesting a potential therapeutic strategy for selective ferroptosis induction in specific tumor sub-populations [66,67]. Here, GPX4 is linked to hepatocellular carcinoma.